Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts

Reuters

2025/12/22

<a href="https://laohu8.com/S/PPCB">Propanc Biopharma</a> Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts

Propanc Biopharma Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2593548400"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593548400\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593548400?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593548400","market":"nz","top_or_hot":-1,"title":"Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PPCB\">Propanc Biopharma</a> Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PPCBD\">Propanc Biopharma</a> Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPropanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-22 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PPCB\">Propanc Biopharma</a> Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PPCBD\">Propanc Biopharma</a> Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL9J1sMQ:1","article_id":"2593548400","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593548400","pubTimestamp":1766404925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Propanc Biopharma Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma  fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","PPCB":"Propanc Biopharma, Inc.","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4112":"金融交易所和数据","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD"},"translate_title":"Propanc Biopharma报告前酶破坏胰腺癌成纤维细胞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PPCB":0.9},"content_text":"Propanc Biopharma Reports Proenzymes Disrupt Pancreatic Cancer Fibroblasts\n    \n\nPropanc Biopharma Inc. and its research partners at the Universities of Jaén and Granada have published new findings in the journal Scientific Reports demonstrating the potential impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts. The study shows that Propanc’s PRP, a combination of bovine-derived pancreatic proenzymes trypsinogen and chymotrypsinogen, has multifaceted effects on cancer-associated fibroblasts and tumor cells within the PDAC tumor microenvironment. These results highlight PRP as a promising candidate for disrupting key tumor interactions and suggest its potential as an adjunct therapy for PDAC patients. Propanc plans to begin a Phase 1b clinical study in advanced cancer patients in the third quarter of 2026 to further investigate PRP’s clinical benefits. The research results have already been published and are available online.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9615825) on December 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}